Media Summary: The first of four Q&A discussion panels from day one of the Advancing Generic Drug Development Conference. This presentation provided an overview of the current use of Comparative Use Human Factors (CUHF) studies to support various ... The second of four Q&A discussion panels from day one of the Advancing Generic Drug Development Conference.
Agdd 2024 D1s05 Q A - Detailed Analysis & Overview
The first of four Q&A discussion panels from day one of the Advancing Generic Drug Development Conference. This presentation provided an overview of the current use of Comparative Use Human Factors (CUHF) studies to support various ... The second of four Q&A discussion panels from day one of the Advancing Generic Drug Development Conference. This presentation explained factors that could impact first-cycle bioequivalence (BE) adequacy based on observed BE ... dissolution issues and examined OGD's bioequivalence evaluation based on the totality of evidence for this case. The session ... The second of three Q&A discussion panels from day two of the Advancing Generic Drug Development Conference.
This presentation provided key principles for comparative analyses (CA) and established understanding of essential CA ... This presentation described content and format requirements for composition statements of drug products and explained what to ... Closing remarks from day one of the Advancing Generic Drug Development Conference delivered by Dr. Sau (Larry) Lee. This presentation discussed the ANDA landscape for topical products applied to the skin and identified challenges associated ... FDA experts demonstrate the FDA's Generic Drug User Fee Amendments (GDUFA) Science and Research Program's ... This presentation identified recent product-specific guidance (PSG) documents that include detailed language regarding the use ...
This presentation informed attendees about FDA's laboratory support for inhalation drug assessment and the research efforts ... The first of three Q&A discussion panels from day two of the Advancing Generic Drug Development Conference. Closing remarks from day two of the Advancing Generic Drug Development Conference delivered by Dr. Robert Lionberger. The final Q&A discussion panel from day one of the Advancing Generic Drug Development Conference. ***No Timestamps*** ... The third of four Q&A discussion panels from day one of the Advancing Generic Drug Development Conference. This presentation discussed in silico methodologies for topical products applied to the skin, with particular focus on dermal ...
The final Q&A discussion panel from day two of the Advancing Generic Drug Development Conference. ***No Timestamps*** ...
